Physician profile
Deborah Henry
NPI 1588751689
$3,226.09
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,637 · 2022: $1,457 · 2023: $102 · 2024: $29.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $343.35 | 2021-2022 | |
| Novo Nordisk INC | $307.60 | 2021-2023 | Wegovy |
| Abbvie INC. | $281.71 | 2021-2023 | |
| Glaxosmithkline, LLC. | $248.76 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $209.01 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $196.80 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.99 | 2021-2023 | Jardiance |
| Amgen INC. | $180.07 | 2021-2022 | |
| Pfizer INC. | $172.46 | 2021-2023 | |
| Esperion Therapeutics, INC. | $155.09 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $149.81 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $137.57 | 2021-2022 | |
| Radius Health, INC. | $109.18 | 2021-2022 | |
| Amarin Pharma, INC. | $95.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $91.47 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30.64 | 2022-2023 | Nexplanon |
| Daiichi Sankyo INC. | $29.99 | 2024 | Injectafer |
| Astellas Pharma US INC | $29.42 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.88 | 2022 | |
| Antares Pharma, INC. | $27.03 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $24.47 | 2021 | |
| Abbott Laboratories | $24.26 | 2021 | |
| Amneal Pharmaceuticals LLC | $22.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.11 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.75 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.46 | 2021 | |
| Eisai INC. | $13.14 | 2021 | |
| Mylan Specialty L.P. | $13.03 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.34 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Genentech USA, INC. | $9.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.